Showing 931-940 of 1043 results for "".
Special Report: Neuro-oncology
https://practicalneurology.com/diseases-diagnoses/imaging-testing/special-report-neuro-oncology-part-ii-management-of-brain-tumors/31624/Part 2. Management of brain tumorsMS Minute: Oral Therapies for MS
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-oral-therapies-for-ms/31607/The advent of oral therapies has ushered in a new phase of disease-modifying treatments.Behavioral Approaches in Dementia Care
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/behavioral-approaches-in-dementia-care/31800/The many behavioral and psychologic symptoms of dementia have a large effect on patient and caregiver outcomes.Treatment of Movement Disorders with Neuromodulation
https://practicalneurology.com/diseases-diagnoses/movement-disorders/treatment-of-movement-disorders-with-neuromodulation/32040/Effective surgical treatments are available for Parkinson disease, essential tremor, and dystonia.- 2024 Brain Health Academy Launches with Free Online Courses/Credits For Health Care Providers About Dementia Risk Reduction Tacticshttps://practicalneurology.com/news/2024-brain-health-academy-launches-with-free-online-coursescredits-for-healthcare-providers-about-dementia-risk-reduction-tactics/2470461/The 2024 Brain Health Academy, a series of educational courses provided by the nonprofit organization UsAgainstAlzheimer’s, will begin on Thursday, May 9, 2024. The online courses are free of charge and are intended to provide health care and wellness providers with tools and resources to a
- Neurostimulation Device for Drug-Resistant Focal Epilepsy Demonstrates Significant, Long-Term Reductions in Seizureshttps://practicalneurology.com/news/neurostimulation-device-for-drug-resistant-focal-epilepsy-demonstrates-significant-long-term-reductions-in-seizures/2474345/Three-year data from a post-approval study (PAS; NCT02403843) of the NeuroPace Responsive Neurostimulation (RNS) System (Mountain View, CA) demonstrated significant and sustained reductions in seizures in adults with drug-resistant focal epilepsy (DRE). The results of the PAS presented at the Ame
- Once-Nightly Sodium Oxybate Highly Preferred in Clinical Studyhttps://practicalneurology.com/news/once-nightly-sodium-oxybate-highly-preferred-in-clinical-study/2469894/According to the questionnaires participants took in the RESTORE study (NCT04451668) for sodium oxybate (FT218; Avadel Pharmaceuticals, Philadelphia, PA) to treat narcolepsy, once-nightly vs twice
- Gene Therapy Safely Delivers Functional Beta-Galactosidase Enzyme Activity to Children with Gangliosidosis 1https://practicalneurology.com/news/gene-therapy-safely-delivers-functional-beta-galactosidase-enzyme-activity-to-children-with-gangliosidosis-1/2469785/In the Imagine-1 phase 1/2 open-label, dose-escalation study (NCT04713475) of gene therapy (PBGM01; Passage Bio, Philadelphia PA) increased functional β-galactosidase activity in children with gangliosidosis type 1 (GM1). Loss of
- Buntanetap Treatment for Parkinson Disease Linked to Improvements in Motor, Non-Motor, and Cognitive Functionshttps://practicalneurology.com/news/buntanetap-treatment-for-parkinson-disease-linked-to-improvements-in-motor-non-motor-and-cognitive-functions/2470527/Treatment with buntanetap (Annovis Bio, Malvern, PA), an oral molecule with potential therapeutic applications in neurodegenerative conditions such as Parkinson disease (PD) and Alzheimer disease (AD), was associated with improvements in motor and non-motor activities and cognitive functions in p
- Improvements in Cognition, Alzheimer Disease Biomarkers Linked to Novel Small Molecule Drughttps://practicalneurology.com/news/improvements-in-cognition-alzheimer-disease-biomarkers-linked-to-treatment-with-buntanetap/2470512/Treatment with buntanetap (Annovis Bio, Malvern, PA), an oral molecule with potential therapeutic applications in neurodegenerative conditions such as Parkinson disease (PD) and Alzheimer disease (AD), was associated with significant improvements in cognition and biomarker measures in people with